Publications
Iorns, E., Lord, C. J., Turner, N. and Ashworth, A. Utilizing RNA interference to enhance cancer drug discovery. Nature Reviews Drug Discovery 6(7):556-68 (2007). Pubmed link
Iorns, E., Turner, N., Elliott, R., Syed, N., Garrone, O., Gasco, M., Tutt, A. N., Crook, T., Lord, C. J. and Ashworth, A. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13(2):91-104 (2008). Pubmed link
Featured in: Swanton, C., Downward, J. Unraveling the complexity of endocrine resistance in breast cancer by functional genomics. Cancer Cell 13(2):83-5 (2008). Pubmed link
Turner, N. C., Lord, C. J., Iorns, E., Brough, R., Swift, S., Elliott, R., Rayter, S., Tutt, A. N. and Ashworth A. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. The EMBO Journal 27(9):1368-77 (2008). Pubmed link
Lord, C. J., Iorns, E. and Ashworth, A. Dissecting resistance to endocrine therapy in breast cancer. Cell Cycle 7(13):1895-8 (2008). Pubmed link
Iorns, E., Lord, C. J., and Ashworth, A. Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochemical Journal 417(1):361-70 (2009). Pubmed link
Iorns, E., Lord, C. J., Grigoriadis, A., McDonald, S., Fenwick, K., McKay, A., Mein, C. A., Natrajan, R., Savage, K., Tamber, N., Reis-Filho, J. S., Turner, N. and Ashworth, A. Integrated functional, gene expression, genomic analysis for the identification of cancer targets. PLoS ONE 4(4):e5120 (2009). Pubmed link
Iorns, E., de Kemp, S., Lord, C.J. and Ashworth, A. CRK7 modifies the MAPK pathway and influences the response to endocrine therapy. Carcinogenesis 30(10):1696-701 (2009). Pubmed link
Turner, N., Pearson, A., Sharpe, R., Lambros, M., Geyer, F., Lopez-Garcia, M. A., Natrajan, R., Marchio, C., Iorns, E., Mackay, A., Gillett, C., Grigoriadis, A., Tutt, A., Reis-Filho, J. S. and Ashworth, A. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Research 70(5):2085-94 (2010). Pubmed link
Iorns, E., Hnatyszyn, J., Seo, P., Clarke, J., Ward, T.M. and Lippman, M. The role of SATB1 in breast cancer pathogenesis. JNCI (Epub July 1, 2010). Pubmed link
Iorns, E., Ward, T. M., Dean, S., Jegg, A., Lord, C. J., Murugaesu, N., Sims, D., Mitsopoulos, C., Fenwick, K., Kozarewa, I., Naceur-Lombarelli, C., Zvelebil, M., Isacke, C., Ashworth, A., Hnatyszyn, J., Pegram, M. and Lippman, M. Whole genome in vivo RNAi screening identifies the Leukemia Inhibitory Factor Receptor as a novel breast tumor suppressor. In submission (June 2010).
*Ward, T. M., *Iorns, E., Liu, X., Kim, P., Singh, S., Dean, S., Jegg, A., Lippman, M., Landgraf, R. and Pegram, M. Novel detection and characterization of truncated ERBB2 receptors in human breast tumors. In submission (July 2010). *These authors contributed equally.
*Wong, J. S., *Iorns, E., *Rheault, M., Ward, T. M., Weber, U., Lippman, M., Faul, C., Mlodzik, M. and Mundel, P. Regulation of RhoA ubiquitination is an essential step of the RhoA GTPase cycle. In submission (July 2010). *These authors contributed equally.
